Tempest Therapeutics, INC DEF 14A proxy statements

Tempest Therapeutics is holding a special meeting of stockholders on July 27, 2026, to vote on proposed amendments to its Certificate of Incorporation.

Tempest Therapeutics is holding a special meeting on June 18, 2026, to seek stockholder approval for the issuance of shares related to warrant exercises, crucial for Nasdaq compliance and company operations.

Tempest Therapeutics announces a strategic asset acquisition of CAR-T cell therapies from Erigen and Factor Bioscience, securing new funding and appointing a new CEO, subject to stockholder approval.

Tempest Therapeutics, Inc. announced the acquisition of a portfolio of CAR T-cell therapy assets from Erigen LLC and Factor Bioscience Inc. in exchange for 8.27 million shares of its common stock.

Tempest Therapeutics is asking stockholders to approve a reverse stock split, ranging from 1-for-2 to 1-for-15, to potentially improve the marketability and liquidity of its common stock.

Tempest Therapeutics, Inc. announces its 2024 Annual Meeting of Stockholders to be held virtually on June 13, 2024, with voting open until June 12, 2024, covering director elections, executive compensation, and auditor ratification.

Tempest Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 13, 2024, featuring proposals for director elections, executive compensation, and auditor ratification.